Movicol Junior Neutral

Macrogol 3350, the active ingredient in Movicol Junior Neutral, is an osmotic laxative presented as an oral solution for oral use. It treats constipation, including functional and occasional constipation, in children and adolescents.

GNH USA supplies Movicol Junior Neutral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movicol Junior Neutral, an osmotic laxative, is used to manage constipation and related functional bowel disorders.

Constipation: softens stools and promotes regular bowel movements in children. Functional constipation: helps restore normal bowel patterns in pediatric functional constipation. Occasional constipation: provides relief from infrequent constipation episodes.

Movicol Junior Neutral may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating - Nausea - Diarrhoea - Flatulence - Abdominal cramps

Serious or Rare Side Effects: - Electrolyte imbalance (e.g., hypernatremia, hypokalemia) - Severe dehydration requiring medical attention

Before initiating therapy, consider the following precautions: - Assess hydration status: ensure adequate fluid intake. - Monitor electrolyte levels: especially in prolonged use. - Use with caution in renal impairment: adjust therapy as advised. - Avoid in known hypersensitivity to macrogol or any listed electrolyte. - Adjust dose in pediatric patients only under prescriber guidance. - Store at room temperature: keep in the original container, protect from moisture.

Movicol Junior Neutral can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Concomitant use with other osmotic laxatives. - High‑dose electrolyte supplements that may exacerbate electrolyte shifts. - Co‑administration with potent diuretics that increase fluid loss.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium, which may increase osmotic load. - Oral antibiotics such as quinolones, whose absorption can be reduced. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients with renal risk.